Navigation Links
Cardiogenesis Corporation to Report 2010 Fourth Quarter and Full-Year Results on March 9th
Date:2/23/2011

IRVINE, Calif., Feb, 23, 2011 /PRNewswire/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) announced that the company will release results for its fourth quarter and full-year ended December 31, 2010 on Wednesday, March 9, 2011.  The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott, its Senior Vice President and Chief Financial Officer, will host an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio broadcast via the Internet at www.cardiogenesis.com.  The call also will be available to investors and analysts by dialing (800) 299-7928 within the U.S. and Canada and (617) 614-3926 from abroad.  The passcode is 10201520.

The webcast will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.  A telephonic playback of the conference call will be available beginning at 8:00 p.m. Eastern time on Wednesday, March 9, 2011 and continue through 8:00 p.m. Eastern time on Wednesday, March 16, 2011.  The replay can be accessed by calling (888) 286-8010 within the U.S. and Canada and (617) 801-6888 from abroad.  The replay passcode is 95647567.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis.  The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina.  Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at www.cardiogenesis.com.


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
3. Cardiogenesis Reports Third Quarter 2009 Results
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
6. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
7. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
8. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
9. Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
10. Cardiogenesis Receives Research Award From Federal Government
11. Cardiogenesis Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):